Annual General Meeting Corporate Update · 1 day ago · MEKi These specific oncology targets...

Annual General Meeting – Corporate UpdateDecember 22, 2020

Private clinical company operating in San Francisco and Calgary

• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi

Company Profile and Highlights

PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi

These specific oncology targets represent the hottest advancement areas in cancer fighting today!

The Cocktail Approach:

MultipleSynergistic Targets



• Registration enabling studies in process for 2021


PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi






• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)


PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi






• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)• ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone


PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi







• National Cancer Institute clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers


PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi







• National Cancer Institute clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers

• Strong partnerships with multinational pharmaceutical companies


PD-1

PD-L1

PARPi

CDK4/6i

ZEN-3694

ARi

BCL2i PI3Ki

CYP17ai

JAKi

MEKi




ZEN-3694 BETi Programs Phase 1 Phase 2 Pivotal

AR independent mCRPC - Prostate (+ enzalutamide)

TNBC (+ talazoparib) - Breast

AR Independent CRPC - Prostate(+ Keytruda + enzalutamide)

Zenith’s Clinical Pipeline (no assigned rights except China)

Other Combinations(+ PARPi,+MEKi, CDK4/6i, chemo)

HR+ breast, CRC, Ovarian, CRPC, NmC

Pre-Clin

Newsoara (China)

Immune-oncology Combinations(+ PD-1 Mab + anti-CTLA4 Mab)

Ovarian, TNBC, Melanoma

Published Prostate Trial DataPrimary resistance to abiraterone data is advancing to Phase 2b/3 in China first

Clinical data and AI platform show that both ZEN-3694 and

enzalutamide required for durable

PSA response

0

5

10

15

20

25

30

35

40

45

-40 -20 0 20 40 60 80 100 120

PSA

ug/

L

Weeks on ZEN-3694

ZEN-3694 + enzalutamide Prior abiraterone

Three patients with significant and durable PSA response, after poor response to abiraterone

Pfizer & Zenith Combination Therapy Study: Triple Negative Breast Cancer (TNBC) Results

Slide material and content compiled by Pfizer Inc.

Study Design


12

Drug and Dosing Combinations


13

Trial Results


14

Trial Conclusions and Results


TNBC Program Highlights Significant Breakthrough in PARP Combo

15

ZEN-3694 + TalazoparibBiomarker selected (N=17)

ZEN-3694+Talazoparib Biomarker unselected (N=13)

All patients (N=30)

ORR % 41% 8% 27%

CBR (> 4 mo) % 59% 29% 45%

CBR (> 6 mo) % 56% 8% 43%

004-

017-

001

(C3)

004-

020-

018

(C3)

004-

012-

048

(C3)

004-

012-

036

(C3)

004-

014-

045

(C3)

004-

012-

007

(C3)

004-

021-

049

(C3)

004-

021-

015

(C3)

004-

016-

034

(C3)

004-

017-

010

(C3)

004-

020-

047

(C3)

004-

020-

038

(C3)

004-

017-

023

(C3)

004-

021-

025

(C3)

004-

011-

022

(C7)

004-

019-

033

(C3)

004-

014-

019

(C3)

004-

019-

035

(C6)

004-

011-

040

(C3)

004-

011-

037

(C5)

004-

019-

046

(C3)

004-

017-

002

(C5)

004-

019-

039

(C3)

004-

018-

014

(C11

)

004-

021-

042

(C3)

004-

021-

030

(C5)

004-

018-

008

(C7)

004-

018-

006

(C5)

004-

018-

020

(C3)

-100

-50

0

50

100

%C

han

ge

in

Ta

rget

Les

ion

s Biomarker selected

Biomarker unselected

PD= 20% increase

PR= 30% decrease


Legend:

PD: Progressive DiseasePR: Partial ResponseORR: Overall Response Rate (Complete Response + Partial Response)CBR: Clinical Benefit Rate (ORR + Stable Disease)

TNBC Program Highlights Significant Breakthrough in PARP Combo

16

ZEN-3694 + TalazoparibBiomarker selected (N=17)

ZEN-3694+Talazoparib Biomarker unselected (N=13)

All patients (N=30)

ORR % 41% 8% 27%

CBR (> 4 mo) % 59% 29% 45%

CBR (> 6 mo) % 56% 8% 43%

004-

017-

001

(C3)

004-

020-

018

(C3)

004-

012-

048

(C3)

004-

012-

036

(C3)

004-

014-

045

(C3)

004-

012-

007

(C3)

004-

021-

049

(C3)

004-

021-

015

(C3)

004-

016-

034

(C3)

004-

017-

010

(C3)

004-

020-

047

(C3)

004-

020-

038

(C3)

004-

017-

023

(C3)

004-

021-

025

(C3)

004-

011-

022

(C7)

004-

019-

033

(C3)

004-

014-

019

(C3)

004-

019-

035

(C6)

004-

011-

040

(C3)

004-

011-

037

(C5)

004-

019-

046

(C3)

004-

017-

002

(C5)

004-

019-

039

(C3)

004-

018-

014

(C11

)

004-

021-

042

(C3)

004-

021-

030

(C5)

004-

018-

008

(C7)

004-

018-

006

(C5)

004-

018-

020

(C3)

-100

-50

0

50

100

%C

han

ge

in

Ta

rget

Les

ion

s Biomarker selected

Biomarker unselected

PD= 20% increase

PR= 30% decrease

TRODELVY(Marketed by Gilead)

ORR = 35%

CBR (> 6 mo) =45%

Legend:

PD: Progressive DiseasePR: Partial ResponseORR: Overall Response Rate (Complete Response + Partial Response)CBR: Clinical Benefit Rate (ORR + Stable Disease)

UCSF-initiated clinical study using Keytruda, Enzalutamide and ZEN-3694 for mCRPC – study design published

2020 Milestones Leading to Major Collaborations

Spun out from Resverlogix Corp. 2013Zenith

Q1-2020

Q2-2020

Q3-2020

Q4-2020

Received US$5M milestone payment from Newsoara (China region partnership) upon successful completion of Ph2 mCRPC US study in combination with enzalutamidePh2 Collaboration with Pfizer

continues (TNBC) – moves towards efficacy stage

NCI CRADA announced. Clinical collaboration for multiple oncology clinical trials with different combination agents

First NCI CRADA study announced, NCI co-collaborating with Zenith and Bristol Myers Squibb (BMS) investigating ZEN-3694 with nivolumab and ipilimumab –in resistant ovarian cancer

Ph2 Collaboration with Pfizer proceeds to final efficacy stage of the Ph2 TNBC trial – advancing towards future registration

Regulatory advancement in China for ph2b/3 mCRPC study – paving way for worldwide development

Annual General Meeting – Questions & AnswersDecember 22, 2020

Annual General Meeting Corporate Update · 1 day ago · MEKi These specific oncology targets...

Documents

Transcript of Annual General Meeting Corporate Update · 1 day ago · MEKi These specific oncology targets...